CN1616009A - Chinese medicine for treating high viscosity blood syndrome and its preparing method - Google Patents
Chinese medicine for treating high viscosity blood syndrome and its preparing method Download PDFInfo
- Publication number
- CN1616009A CN1616009A CN 200410073137 CN200410073137A CN1616009A CN 1616009 A CN1616009 A CN 1616009A CN 200410073137 CN200410073137 CN 200410073137 CN 200410073137 A CN200410073137 A CN 200410073137A CN 1616009 A CN1616009 A CN 1616009A
- Authority
- CN
- China
- Prior art keywords
- blood
- high viscosity
- chinese medicine
- radix
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to Chinese medicine for treating high viscosity blood syndrome and its preparation process. High viscosity blood syndrome and thrombosis will result in many kinds of cardiac and cerebral vascular diseases. The Chinese medicine has astragalus root and Chuanxiong rhizome with functions of benefiting vital energy and promoting blood circulation as main component, earthworm and rhubarb with functions of dispersing blood stasis and dredging meridian as adjuvant component, and desert cistanche, sealwort, red sage and curcuma root as assistant component. The Chinese medicine has obvious curative effect on coronary heart disease, angina pectoris, hypertension, etc. and no toxic side effect.
Description
One, technical field:
The present invention relates to a kind of Chinese medicine for the treatment of blood high viscosity syndrome and preparation method thereof.
Two, background technology:
Blood high viscosity syndrome and thrombosis are numerous diseases, pathological change basis as ischemic cardiovascular and cerebral vascular diseases such as coronary heart disease, myocardial infarction, hypertension, apoplexy, cerebral arteriosclerosis, the serious threat human beings'health, the hazardness of cardiovascular and cerebrovascular disease and universality, scientific circles pay attention to the research of its pathology, focus and pathogenesis for a long time always.Many gratifying progress and achievement have been obtained for many years.As: operate on methods such as operation, hemodialysis, blood vessel dilating and medicine blood vessel dilating, thrombolytic, embolism extinguishing.These methods have much effect, but corresponding surgical risk and high medical fee while tool exist.And frequent Ahylysantinfarctase, aspirin, heparin and the oral coumarin etc. used on the clinical drug.Along with deepening continuously of medical basic research, people are to the multiple live body factor of participation cardiovascular and cerebrovascular disease and the understanding gradually of associated receptor.Find that these clinical drug utilizations have many drawbacks or limitation, for example, recently learn in the meeting the doctor of U.S. brain section, a result of study of announcing from the personnel of Pasteur Institut shows: cut out aspirin suddenly the cardiac is worked the mischief, may cause heart attack.That is to say that the toxic and side effects that medicine produces is the problem that makes doctor and patient's headache always.
Three, summary of the invention:
The object of the present invention is to provide a kind of Chinese medicine that is used for the treatment of blood high viscosity syndrome and good effect, can takes for a long time, have no side effect and preparation method thereof.
For achieving the above object, the technical solution used in the present invention is:
A kind of Chinese medicine for the treatment of blood high viscosity syndrome, its special character is: the Chinese medicine of described treatment blood high viscosity syndrome is the medicament of being made by following materials of weight proportions:
Radix Astragali 360-440 part Radix Salviae Miltiorrhizae 180-220 part Herba Cistanches 180-220 part
Radix Curcumae 90-110 part Rhizoma Chuanxiong 180-220 part Fructus Crataegi 180-220 part
Rhizoma Polygonati 180-220 part Semen Ginkgo 45-55 part Radix Et Rhizoma Rhei 45-55 part
Pheretima 45-55 part
The Chinese medicine of above-mentioned treatment blood high viscosity syndrome is the medicament of being made by following materials of weight proportions:
100 parts of 200 portions of Radix Curcumaes of 200 parts of Herba Cistanches of 400 parts of Radix Salviae Miltiorrhizaes of the Radix Astragali
50 parts of 200 portions of Semen Ginkgoes of 200 parts of Rhizoma Polygonatis of 200 portions of Fructus Crataegis of Rhizoma Chuanxiong
50 parts of 50 parts of Pheretimas of Radix Et Rhizoma Rhei
Above-mentioned medicament is the above a dosage form of any pharmaceutics.
Above-mentioned dosage form is tablet, pill, capsule.
A kind of preparation method of Chinese medicine for the treatment of blood high viscosity syndrome, its dosage form are that the processing step of preparation method of tablet is as follows:
(1), with above ten flavor, get Rhizoma Chuanxiong, Radix Et Rhizoma Rhei, Pheretima half and half amount and all the other 7 flavors, decoct with water three times, add 8 times of amounts of water for the first time, decocted 1.5 hours, second and third time respectively adds 6 times of amounts of water, decocted 1 hour, and merged three times decocting liquid, filter, with filtrate be concentrated into when temperature is 60 ℃, filtrate is concentrated into the ointment that relative density is 1.25-1.30, and is standby.
(2), remaining Rhizoma Chuanxiong, Radix Et Rhizoma Rhei, Pheretima powder are broken into fine powder, sieve mixing, add the ointment of above-mentioned steps (1) preparation, stir, add 3% dextrin, stir, oven dry is ground into fine powder, add ethanol and granulate 60 ℃ of oven dry, granulate in right amount, add 1% magnesium stearate again, mixing, compacting is in blocks, promptly.
The present invention is with respect to prior art, and it is started with from improving, recover cardiovascular inwall function, and protection surrounding tissue cell reduces cholesterol and accumulates, and plays a part arteriosclerosis.
The present invention has significant improvement effect to hemorheological property, thereby reduces the viscosity of blood.
It is rigorous that the present invention has prescription, and the compatibility science is evident in efficacy, can bring into play curative effect of medication to a greater extent, and instant effect has no side effect, and can take for a long time, and clinical advantage such as safe in utilization is for the treatment blood high viscosity syndrome has been started brand-new approach.
Four, specific embodiment:
Though it is considered herein that the cause of disease of blood high viscosity syndrome and ischemic heart disease and thrombotic disease is comparatively complicated, but blood stasis due to qi deficiency is the intrinsic factor of morbidity, the blood brain is obstructed to be the pathologic basis that constitutes the primary disease morbidity, treatment should turn round and look at specimen two, mend let out develop simultaneously, benefiting qi and removing blood stasis, purging FU-organs dredge network, multitudinous proving effective, so with QI invigorating, invigorate blood circulation, dredge network, benefit, kidney is for ruling by law.
Ancient Chinese medicine does not have this diagnosis of blood high viscosity syndrome.This disease belongs to the traditional Chinese medical science " blood stasis " category, and its pathogenesis is that blood moves in arteries and veins and loses " pulse felt like the flowing of water without return " normal manner, makes blood " coagulate and do not flow ", insufficiency of vital energy and blood and the disease that arrives, the rule of treatment make its accent reach with promoting circulation of QI-blood and make peace flat, excess syndrome of blood should be treated by blood letting, the deficiency of vital energy should sincerely be drawn it.This side abides by that " purport of interior warp with benefiting QI for activating blood circulation cube, is reused the Radix Astragali, Rhizoma Chuanxiong is monarch, benefiting QI for activating blood circulation in the side; With Pheretima, Radix Et Rhizoma Rhei dissipating blood stasis, collateral dredging is a minister; Herba Cistanches, Rhizoma Polygonati are assistant to set upright; Radix Salviae Miltiorrhizae, Radix Curcumae circulation of qi promoting treating blood disorders are drawn all medicines to reach blood vessels are the messenger drug treating both the principal and secondary aspects of a disease, reach the purpose of benefiting QI for activating blood circulation, dredging the meridian, are applicable to the prevention and the treatment of blood high viscosity syndrome, ischemic cardiovascular and cerebral vascular disease, thrombosis sexually transmitted disease (STD) disease.
The present invention is directed to the popular characteristics of China's cardiovascular and cerebrovascular disease, foundation is clinical experience all the year round, in conjunction with motherland's medical science " stagnation of QI; blood stop up do not flow " is the main cause of morbidity, its pathogenesis is, the theory of " wet is not all right; in blood coagulation is accumulate; body fluid is puckery with fixed attention, can not ooze form long-pending " (virtuous Wonderful Well-Tried Recipes 11 volumes in bright, side), collection modern medicine study achievement.Solely split new footpath proposition high viscous blood obstacle be the main cause that causes cardiovascular and cerebrovascular disease, solve the root problem that blood high viscosity syndrome can solve cardiovascular disease prevention.
Attach most importance to soldier in blood high viscosity syndrome and complication atherosclerosis (AS) thereof, thrombosis, the brain, to reinvent blood vessel elasticity is the breach, with cardiovascular surrounding tissue active substance is the center, first line of a couplet gene, under be function, on the cause of disease, pathogeny and 3 levels that connect each other of control, carry out the basic aspect research of blood high viscosity syndrome pathogenesis and control.
It is to start with from the microcirculation aspect that the present invention solves blood high viscosity syndrome, the level and atherosclerosis (AS) morbidity that propose plasma high density fat egg HDL and blood plasma low density lipoprotein, LDL reduction LDL have substantial connection, set forth LDL rising in the blood, cholesterol can cause the generation of atherosclerosis (AS) in the cell inner accumulated.The function of HDL is to participate in the process that cholesterol is overflowed in a organized way, thereby protection surrounding tissue cell reduces cholesterol and accumulates, and plays a part arteriosclerosis.High density lipoprotein pair increases with the ldl ratio value, can prevent, alleviates and resist the influence that other lipids form atherosclerosis (AS).By the variation (mmoI/L) before and after five treatments of following table blood fat
Variation before and after five treatments of blood fat of the present invention:
Project | Before the treatment | After the treatment | Inequality | The P value |
Cholesterol | 4.3373 | ?4.6467 | ?0.2694 | <0.01 |
Triglyceride | 1.7629 | ?1.8699 | ?0.1071 | <0.05 |
HDL?1 | 1.4568 | ?1.6747 | ?0.2179 | <0.01 |
HDL?2 | 0.8993 | ?0.9676 | ?0.0683 | <0.05 |
HDL?3 | 0.4779 | ?0.5033 | ?0.0254 | <0.05 |
Show the present invention's blood viscosity lowering significantly, delayed the development of atherosclerosis (AS).Result of study proposes the method and the measure of blood high viscosity syndrome early warning diagnosis and early prevention, and provides brand-new thinking for diagnosis, prevention and the treatment of China's cardiovascular and cerebrovascular disease.
By the second clinical medicine institute of Xian Medical Univ, Tang of The Fourth Military Medical University all four tame authoritative hospitals such as hospital, the hospital of traditional Chinese hospital, Xi'an, Hospitai of Xi-an Electric Power Center carry out 305 routine clinical observations research:
Wherein 275 examples are organized in treatment, male's 183 examples, women's 92 examples, maximum 74 years old age, minimal ages 20 years old; Matched group (aspirin) 30 examples, male's 24 examples wherein, women's 6 examples, maximum 74 years old age, minimal ages 24 years old.Relating to multiple disease, age, sick kind and curative effect distributes as follows:
The data that four tame authoritative hospitals carry out clinical observation research all prove: the present invention to the thoracic obstruction of congestion internal resistance, deficiency of heart-blood, disease such as dizzy uncomfortable in chest, breathe hard, cardiopalmus, dizziness, disease (coronary heart disease of modern medicine, angina pectoris, hypertension, cerebral arteriosclerosis such as weak, apoplexy, sequela, diseases such as TIA) improvement has the produce effects curative effect, its effect is better than aspirin, and has no side effect.Total effective rate reaches more than 90%, is mainly used in middle-aged and elderly people blood high viscosity syndrome and the thrombotic multiple disease prevention and the treatments of suffering from more.
Below two tables for Drug therapy blood high viscosity syndrome curative effect of the present invention statistics and medicine of the present invention, aspirin blood viscosity lowering curative effect relatively:
Drug therapy blood high viscosity syndrome curative effect statistics of the present invention
Treatment back inequality P value before the project treatment
The whole blood height is cut viscosity 7.9021 6.8791 1.0230<0.01
The low viscosity 20.7849 16.2369 4.5480<0.01 of cutting of whole blood
Plasma viscosity 1.7402 1.6241 0.1161<0.01
RBC hematocrit 44.2900 43.8600 0.4300<0.05
Height is cut reduced viscosity 7.7943 7.3521 0.4422<0.01
The low reduced viscosity 25.8556 23.2092 2.6465<0.05 of cutting
RBC aggregate index 2.8277 2.5380 0.2907<0.01
RBC rigidity index 1.0092 0.9914 0.0178<0.05
RBC sedimentation rate 22.4947 20.5600 1.9437<0.05
ESR equation K value 78.2700 76.2700 2.0000<0.05
Fibrinogen quantitative 0.3696 0.3696 0.003<0.05
Medicine of the present invention, aspirin blood viscosity lowering curative effect are relatively
Project medicine group of the present invention aspirin group P value
The whole blood height is cut viscosity 1.0230 0.1890<0.01
The low viscosity 4.5480 2.5230<0.05 of cutting of whole blood
Plasma viscosity 0.1161 0.0063<0.01
RBC hematocrit 0.4300 0.4287<0.05
Height is cut reduced viscosity 0.4422 0.1375<0.05
The low reduced viscosity 2.6465 2.9340<0.05 of cutting
RBC aggregate index 0.2907 0.2680<0.05
RBC rigidity index 0.0178 0.0192<0.05
RBC sedimentation rate 1.9347 1.9670<0.05
ESR equation K value 2.0000 0.3333<0.05
Fibrinogen quantitative 0.0003 0.0310<0.05
Thereby show that its effect is better than aspirin, and have no side effect.Total effective rate reaches more than 90%.
Xian Medical Univ's clinical pharmacology institute is reported as follows toxicological test of the present invention:
Toxic reaction carries out the test of urgency poison when Cmax of the present invention, maximum volume.Irritate stomach by white mice being carried out 3 times on the one drug extract powder of the present invention, observed continuously 10 days, mice all survives, spirit, activity freely, diet is normal, hair is glossy, weight increase.Cumulative maximum dosis tolerata 30g/kg (being equivalent to primary crude drug 150g/kg) is more than 400 times of clinical consumption.
Toxic reaction of the present invention carries out slow poison test:
1. the observation of general situation: show that the weight of animals is subjected to the influence of medicine not obvious.
2. hematological examination: heavy dose of group glutamate pyruvate transaminase obviously descends, and serum total cholesterol obviously rises, and makes comparisons with matched group respectively, nonsignificance (P>0.05).Illustrate that the two returns to normal level gradually.
3. histopathologic examination: histological examinations such as the heart, lung, brain, gastric mucosa, kidney, cuirass shape adrenal gland, testis, ovary, uterus, with the blank group relatively, do not see that tangible pathologic changes.
The anxious poison of Xian Medical Univ's clinical pharmacology institute, slow malicious test report prove that all the present invention has no side effect, and can take for a long time.
Xian Medical Univ's clinical pharmacology institute is to the test report of drug effect of the present invention:
1. observe the present invention to the microcirculatory influence of rat mesentery: the present invention can be used for treating blood high viscosity syndrome.In order to study its pharmacological action, we are experimental subject with the rat, and having observed the present invention is microcirculatory effect to the rat goldbeater's skin.The result: dosage of the present invention and middle dosage can significantly be expanded the rat mesentery blood capillary, quicken capillary blood flow speed, increase the open quantity of blood capillary.Show: the present invention has the microcirculatory effect of the mesentery of improvement.
2. observe the present invention causes the high viscosity mass formed by blood stasis of rabbit to macromolecule right rotary glycoside influence: observe the present invention causes the high viscosity blood of rabbit model prevention administration to macromolecule right rotary glycoside effect.The result shows: the heavy dose of group of the present invention compares with high blood viscosity liquid model group, can not only significantly reduce the blood height and cut viscosity, and low viscosity (P<0.01) plasma viscosity of cutting reduces packed cell volume, and can significantly reduce erythrocyte and build up index.Dosage group among the present invention is removed this parameter influence of plasma viscosity when little, to the influence of the hemorheology index of high blood viscosity liquid, all organizes with heavy dose of.In contrast, low dose of the present invention is not remarkable to the effect that improves hemorheological indexes.In a word, the present invention has and improves the surge hemorheological effect of object model of high blood viscosity significantly.
3. observe the present invention and cause the effect that the high viscosity blood of rabbit model is treated administration revolving glucosides in the macromolecule.The result: the present invention has its hemorheological effect of remarkable reduction to the pathological model of the high viscosity blood of rabbit.The present invention compares with blank group, significantly reduces the whole blood height and cuts viscosity, and hang down and cut viscosity, reduced viscosity, packed cell volume and erythrocyte are built up the fat number.Show: the present invention causes the high viscosity blood of rabbit model to macromolecule right rotary glycoside and has significant therapeutic effect.
4. observe the influence of the present invention to the rat experiment hypercholesterolemia: the result confirms: when with the hypercholesterolemia model group relatively the time, and the middle dosage in the present invention's test and significantly reduce serum total cholesterol content.Illustrate that the present invention has the pharmacological action of cholesterol reducing.
5. observe the influence that the present invention forms the rabbit external thrombus: the result: the heavy dose of group of medicine of the present invention is compared with high viscosity blood model group, and (rabbit 2.0g/kg) can significantly shorten the thrombosis length of external formation to heavy dose of medicine of the present invention, reduces its weight.Show: the present invention has the effect of the thrombosis of inhibition.
6. the present invention is to the influence of rat immunity function: experimental result: each dosage group of medicine of the present invention all can obviously improve the content of E rosette.Show that the present invention has potentiation to body's immunity.
7. observe the influence of the present invention to rat immunoglobulin content: experimental result shows: heavy dose of group of medicine of the present invention and middle dosage group can significantly improve Immunoglobulin IgA and IgG content in the rat body.Proof: the present invention has potentiation to body's immunity.The clinical observation on the therapeutic effect total effective rate is more than 90%.And have no side effect, can take for a long time.
Model case:
1, Zhang, woman, 51 years old, admission number: 1927
The patient is with dizziness, and weak companion right side human body numbness is hospitalized 4 sections in the hospital of traditional Chinese hospital, Xi'an.The rheology of having a blood test, leading indicator increases, and is high sticking shape.
Have a medical check-up: red tongue with thin fur, sublingual vein blood stasis, stringy and thready pulse.
Dialectical: apoplexy, apoplex involving the channels and collaterals, blood stasis due to qi deficiency.
The rule of treatment: blood circulation promoting and blood stasis dispelling.
Side's medicine: medicine of the present invention, each 5, day clothes 3 times.The top is after 2 weeks of clothes, and aforementioned each symptom all disappears.Pulse condition, inspection of the tongue also takes a turn for the better, the check hemorheology, every index is all reduced to normally.
2, the king so-and-so, the woman, 63 years old, live east, Xi'an No. four institutes in 10 one lanes, 95.8.18 to 9.20 goes to a doctor in the outpatient service of the hospital of traditional Chinese hospital, Xi'an.
The patient was with episodic vertigo 7 years, and is very dizzy during outbreak, and blurring of vision with nausea and vomiting, continues several minutes at every turn.The doctor trained in Western medicine inspection is diagnosed as vertebra basilar artery ischemia vertigo, and companion's essential hypertension was once taken the sharp sheet of Kapp, XUANYUNNING sheet, Semen Ziziphi Spinosae mind calming capsule; Quiet Radix Salviae Miltiorrhizae, Cortex Acanthopanacis Radicis is two courses of treatment respectively; The HeNei Intravascular Laser Irradiation on Blood 5 times and the decoction that takes traditional Chinese medicine, unsatisfactory curative effect.Blood pressure is 21/13kpa.
95.9.22 further consultation is had a medical check-up, tongue is dark, and is fat, and there is indentation on the limit, and arteries and veins is dizzy thin, diagnose dizzy, blood stasis due to qi deficiency, blood high viscosity syndrome, the rheology index of having a blood test is unusual, platelet aggregation increases, whole blood viscosity and plasma viscosity all increase, the nail fold microcirculation obstacle.Begin to take medicine of the present invention, each 5, obey every day 3 times, serve on 15.
95.10.15 further consultation again, medicine of the present invention takes, and dizzy symptom is more preceding obviously to be alleviated, conscious clearheaded, sleeps.Blood pressure is 20/12kpa.With check hemorheology and nail fold microcirculation, the result before is clearly better.
3, patient Xing Baoshan, male, 72 years old, because of uncomfortable in chest, precordialgia, nervous, breathe hard and went into all hospitals of Tang of The Fourth Military Medical University in 1 year, be diagnosed as coronary heart disease, effort angina after being admitted to hospital on inspection, artrial premature beat takes place frequently, cardiac function III level, blood examination finds that the whole blood height is cut viscosity: 7.162mpas, low viscosity: the 20.32mpas, plasma viscosity: 1.74mpas of cutting of whole blood.The whole blood height is cut reduction degree: 7.402mpas, low reduction degree: the 25.36mpas that cuts of whole blood, all be higher than normal value, take 5 of medicines of the present invention, 3 times/day, treat after 15 days check, the above-mentioned index that increases is all reduced to normal range, and symptom is alleviated gradually to share other drug treatment back angina pectoris, have palpitation, breathe hard etc.
4, patient Zhang Weihe, male, 22 years old, because of the nervous all hospitals of 2 Tang of monthly income The Fourth Military Medical University that breathe hard after the activity, be diagnosed as dilated cardiomyopathy after being admitted to hospital, cardiac function III level, hemorheology shows, the whole blood height is cut viscosity, the low viscosity, plasma viscosity of cutting of whole blood, packed cell volume increases, take 5 of medicines of the present invention, 3 times/day, treat after 15 days three of checks and increase index and all recover normal.Share the other drug treatment, the heart failure basic controlling reaches the clinical cure standard and leaves hospital.
5, patient Jiang, the man, 61 years old, excuse dusk, uncomfortable in chest, asthenia power was diagnosed as the hypertension III phase to Xi'an electric power hospital admission, companion's blood high viscosity syndrome.Successively take nifedipine, FUFANG DANSHEN PIAN, glue thigh orchid, propylene glycol alginate sodium sulfate reach 1 year surplus, the check hemorheology still is a blood high viscosity syndrome.Change clothes medicine of the present invention, every day 3 times, each 5, the check hemorheology is learned index behind the first quarter moon, and the result shows: obviously improve.
6, Zhang, man, 53 years old, cadre, admission number 932480.Patient's chest distress and palpitation symptoms several years, labor is sweating then, and the companion is dizzy, and body is tired weak, it is invalid to control for a long time, goes into the second clinical medicine institute of Xian Medical Univ, checks that blood viscosity significantly raises, blood fat also increases, be diagnosed as coronary heart disease (Chinese medical discrimination is a deficiency of heart-blood), companion's blood high viscosity syndrome, hyperlipidemia.Obey medicine of the present invention after two weeks in August, 1992, symptom obviously alleviates.Substantially disappear through obeying a course of therapy symptom.Check hemorheological property and blood fat, it is normal that every index is all recovered.
Embodiment 1:
Radix Astragali 400g Radix Salviae Miltiorrhizae 200g Herba Cistanches 200g Radix Curcumae 100g
Rhizoma Chuanxiong 200g Fructus Crataegi 200g Rhizoma Polygonati 200g Semen Ginkgo 50g
Radix Et Rhizoma Rhei 50g Pheretima 50g
Embodiment 2:
Radix Astragali 360g Radix Salviae Miltiorrhizae 180g Herba Cistanches 180g Radix Curcumae 90g
Rhizoma Chuanxiong 180g Fructus Crataegi 180g Rhizoma Polygonati 180g Semen Ginkgo 45g
Radix Et Rhizoma Rhei 45g Pheretima 45g
Embodiment 3:
Radix Astragali 440g Radix Salviae Miltiorrhizae 220g Herba Cistanches 220g Radix Curcumae 110g
Rhizoma Chuanxiong 220g Fructus Crataegi 220g Rhizoma Polygonati 220g Semen Ginkgo 55g
Radix Et Rhizoma Rhei 55g Pheretima 55g
Its preparation process following steps of the production tablet of the above embodiments 1,2,3:
More than ten flavors, get Rhizoma Chuanxiong, Radix Et Rhizoma Rhei, Pheretima half and half amount and all the other 7 flavors, decoct with water three times, add 8 times of amounts of water for the first time, decocted 1.5 hours, second and third time respectively adds 6 times of amounts of water, decocts 1 hour, merges three times decocting liquid, filter, filtrate is concentrated into relative density and is 1.25-1.30 (60 ℃), and is standby.Remaining Rhizoma Chuanxiong, Radix Et Rhizoma Rhei, Pheretima powder are broken into fine powder, sieve mixing, add above-mentioned ointment, stir, add 3% dextrin, stir, oven dry is ground into fine powder, add ethanol and granulate 60 ℃ of oven dry, granulate in right amount, add 1% magnesium stearate again, mixing is pressed into 1000, promptly.
The above embodiments production dosage form also can be pill, capsule etc.
Claims (5)
1, a kind of Chinese medicine for the treatment of blood high viscosity syndrome is characterized in that: the Chinese medicine of described treatment blood high viscosity syndrome is the medicament of being made by following materials of weight proportions:
Radix Astragali 360-440 part Radix Salviae Miltiorrhizae 180-220 part Herba Cistanches 180-220 part
Radix Curcumae 90-110 part Rhizoma Chuanxiong 180-220 part Fructus Crataegi 180-220 part
Rhizoma Polygonati 180-220 part Semen Ginkgo 45-55 part Radix Et Rhizoma Rhei 45-55 part
Pheretima 45-55 part
2, a kind of Chinese medicine for the treatment of blood high viscosity syndrome according to claim 1, it is characterized in that: the Chinese medicine of described treatment blood high viscosity syndrome is the medicament of being made by following materials of weight proportions:
100 parts of 200 portions of Radix Curcumaes of 200 parts of Herba Cistanches of 400 parts of Radix Salviae Miltiorrhizaes of the Radix Astragali
50 parts of 200 portions of Semen Ginkgoes of 200 parts of Rhizoma Polygonatis of 200 portions of Fructus Crataegis of Rhizoma Chuanxiong
50 parts of 50 parts of Pheretimas of Radix Et Rhizoma Rhei
3, a kind of Chinese medicine for the treatment of blood high viscosity syndrome according to claim 1 and 2 is characterized in that: described medicament is the above a dosage form of any pharmaceutics.
4, a kind of Chinese medicine for the treatment of blood high viscosity syndrome according to claim 3, it is characterized in that: described dosage form is tablet, pill, capsule.
5, a kind of Chinese medicine for the treatment of blood high viscosity syndrome according to claim 4 is characterized in that: described dosage form is that the processing step of preparation method of tablet is as follows:
(1), with above ten flavor, get Rhizoma Chuanxiong, Radix Et Rhizoma Rhei, Pheretima half and half amount and all the other 7 flavors, decoct with water three times, add 8 times of amounts of water for the first time, decocted 1.5 hours, second and third time respectively adds 6 times of amounts of water, decocted 1 hour, and merged three times decocting liquid, filter, with filtrate be concentrated into when temperature is 60 ℃, filtrate is concentrated into the ointment that relative density is 1.25-1.30, and is standby.
(2), remaining Rhizoma Chuanxiong, Radix Et Rhizoma Rhei, Pheretima powder are broken into fine powder, sieve mixing, add the ointment of above-mentioned steps (1) preparation, stir, add 3% dextrin, stir, oven dry is ground into fine powder, add ethanol and granulate 60 ℃ of oven dry, granulate in right amount, add 1% magnesium stearate again, mixing, compacting is in blocks, promptly.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410073137 CN1616009A (en) | 2004-10-10 | 2004-10-10 | Chinese medicine for treating high viscosity blood syndrome and its preparing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410073137 CN1616009A (en) | 2004-10-10 | 2004-10-10 | Chinese medicine for treating high viscosity blood syndrome and its preparing method |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1616009A true CN1616009A (en) | 2005-05-18 |
Family
ID=34765267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410073137 Pending CN1616009A (en) | 2004-10-10 | 2004-10-10 | Chinese medicine for treating high viscosity blood syndrome and its preparing method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1616009A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102319401A (en) * | 2011-09-26 | 2012-01-18 | 西安碑林药业股份有限公司 | A kind of Chinese medicine composition that is used for benefiting QI for activating blood circulation, spleen invigorating collateral dredging and preparation method thereof |
CN102319399A (en) * | 2011-09-26 | 2012-01-18 | 西安碑林药业股份有限公司 | Traditional Chinese medicine composition used for treating coronary heart disease and cerebral arteriosclerosis, and preparation method thereof |
CN102614266A (en) * | 2012-04-20 | 2012-08-01 | 朱遂勤 | Drug for treating hypertension and hyperlipidemia |
CN106177798A (en) * | 2016-08-29 | 2016-12-07 | 戚清春 | A kind of old applicable side and preparation method thereof |
-
2004
- 2004-10-10 CN CN 200410073137 patent/CN1616009A/en active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102319401A (en) * | 2011-09-26 | 2012-01-18 | 西安碑林药业股份有限公司 | A kind of Chinese medicine composition that is used for benefiting QI for activating blood circulation, spleen invigorating collateral dredging and preparation method thereof |
CN102319399A (en) * | 2011-09-26 | 2012-01-18 | 西安碑林药业股份有限公司 | Traditional Chinese medicine composition used for treating coronary heart disease and cerebral arteriosclerosis, and preparation method thereof |
CN102319399B (en) * | 2011-09-26 | 2013-01-23 | 西安碑林药业股份有限公司 | Traditional Chinese medicine composition used for treating coronary heart disease and cerebral arteriosclerosis, and preparation method thereof |
CN102319401B (en) * | 2011-09-26 | 2013-01-23 | 西安碑林药业股份有限公司 | Traditional Chinese medicine composition for tonifying qi and invigorating blood circulation, invigorating spleen and dredging collaterals |
CN102614266A (en) * | 2012-04-20 | 2012-08-01 | 朱遂勤 | Drug for treating hypertension and hyperlipidemia |
CN106177798A (en) * | 2016-08-29 | 2016-12-07 | 戚清春 | A kind of old applicable side and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1840128A (en) | Medicine for treating cardiovascular disease | |
CN1824177A (en) | Medicinal composition for treating hypertension, its preparation method and use | |
CN1628760A (en) | Traditional Chinese medicinal formulation for treating cardiovascular and cerebrovascular disease | |
CN1965966A (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
CN1112836A (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
CN1660395A (en) | Formula of treating apoplexy | |
CN1288748A (en) | Medicine for treating cardiac and cerebral vascular diseases and its preparation | |
CN100358568C (en) | Medicine for treating high blood pressure and its preparation method | |
CN1733242A (en) | Medicine for curing qi deficiency induced thoracic obstruction (coronary heart disease) and technique for preparing the same | |
CN1883533A (en) | Pharmaceutical composition for treating apoplexy and preparation method thereof | |
CN1616009A (en) | Chinese medicine for treating high viscosity blood syndrome and its preparing method | |
CN1232279C (en) | Antilipemic Chinese medicine | |
CN105267889A (en) | Traditional Chinese medicine preparation for treating hyperlipoidemia | |
CN105106758A (en) | Traditional Chinese medicine composition for treating phlegm and blood stasis type dizziness | |
CN1857607A (en) | Chinese medicine preparation for treating cardiac and cerebral vascular diseases and its preparing process | |
CN100344318C (en) | Medicine for treating apoplectic sequel and prepn. thereof | |
CN1111054C (en) | Medicine for treating apoplexy and its preparing process | |
CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
CN1520862A (en) | Prepared traditional Chinese medicine for apoplexy and obstruction of qi in the chest | |
CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
CN1296087C (en) | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof | |
CN1086586C (en) | Medicine for treating cardiac and cerebral vascular diseases and its preparation | |
CN1883660A (en) | Blood fat-reducing Chinese medicine and preparation method thereof | |
CN1814163A (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
CN1253188C (en) | Medicine for treating hypertension and its preparing process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |